These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38111216)

  • 1. The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
    Sicignano D; Hernandez AV; Schiff B; Elmahy N; White CM
    Curr Med Res Opin; 2024 Feb; 40(2):293-302. PubMed ID: 38111216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of psilocybin in addiction: A systematic review.
    van der Meer PB; Fuentes JJ; Kaptein AA; Schoones JW; de Waal MM; Goudriaan AE; Kramers K; Schellekens A; Somers M; Bossong MG; Batalla A
    Front Psychiatry; 2023; 14():1134454. PubMed ID: 36846225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
    Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
    Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial).
    Jensen ME; Stenbæk DS; Juul TS; Fisher PM; Ekstrøm CT; Knudsen GM; Fink-Jensen A
    BMJ Open; 2022 Oct; 12(10):e066019. PubMed ID: 36241352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).
    Beutler BD; Shinozuka K; Tabaac BJ; Arenas A; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e104-e111. PubMed ID: 38518267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users.
    Klimas J; Tobin H; Field CA; O'Gorman CS; Glynn LG; Keenan E; Saunders J; Bury G; Dunne C; Cullen W
    Cochrane Database Syst Rev; 2014 Dec; (12):CD009269. PubMed ID: 25470303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression.
    Henssler J; Müller M; Carreira H; Bschor T; Heinz A; Baethge C
    Addiction; 2021 Aug; 116(8):1973-1987. PubMed ID: 33188563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of brief alcohol interventions in primary care populations.
    Kaner EF; Beyer FR; Muirhead C; Campbell F; Pienaar ED; Bertholet N; Daeppen JB; Saunders JB; Burnand B
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004148. PubMed ID: 29476653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM; Weisman N; Dalo J
    Ann Pharmacother; 2023 Sep; 57(9):1062-1075. PubMed ID: 36635883
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.